The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Corvus Pharmaceuticals Inc (NASDAQ: CRVS) closed at $6.98 down -2.92% from its previous closing price of $7.19. In other words, the price has decreased by -$2.92 from its previous closing price. On the day, 0.79 million shares were traded. CRVS stock price reached its highest trading level at $7.37 during the session, while it also had its lowest trading level at $6.95.
Ratios:
For a deeper understanding of Corvus Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.91 and its Current Ratio is at 8.91. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on January 02, 2025, initiated with a Buy rating and assigned the stock a target price of $11.
On August 18, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 27 ’25 when ORBIMED ADVISORS LLC sold 1,176,332 shares for $4.16 per share. The transaction valued at 4,891,894 led to the insider holds 7,165,006 shares of the business.
Thompson Peter A. sold 1,176,332 shares of CRVS for $4,891,894 on Jun 27 ’25. The Director now owns 7,165,006 shares after completing the transaction at $4.16 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRVS now has a Market Capitalization of 520108000 and an Enterprise Value of 446784000.
Stock Price History:
The Beta on a monthly basis for CRVS is 0.56, which has changed by 0.17508423 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, CRVS has reached a high of $10.00, while it has fallen to a 52-week low of $2.54. The 50-Day Moving Average of the stock is 24.82%, while the 200-Day Moving Average is calculated to be 52.25%.
Shares Statistics:
For the past three months, CRVS has traded an average of 595.63K shares per day and 935320 over the past ten days. A total of 74.51M shares are outstanding, with a floating share count of 54.39M. Insiders hold about 27.01% of the company’s shares, while institutions hold 36.92% stake in the company. Shares short for CRVS as of 1757894400 were 9670508 with a Short Ratio of 16.24, compared to 1755216000 on 9294023. Therefore, it implies a Short% of Shares Outstanding of 9670508 and a Short% of Float of 16.420001.
Earnings Estimates
The stock of Corvus Pharmaceuticals Inc (CRVS) is currently being evaluated by 4.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.06 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.09 and -$0.18 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is -$0.62, with 4.0 analysts recommending between -$0.56 and -$0.69.
